Ruxolitinib phosphate tablet patent according to smpc?

I can help with that, but I need a bit more detail to give exact patent numbers and expiry dates.

Questions:
- Which product/jurisdiction do you mean? EU SMPC for Jakavi (ruxolitinib) or US SmPC for Jakafi, or a generic product?
- Do you want the full list of patents cited in the SMPC, or just a summary of whether patents cover the active ingredient, the salt (ruxolitinib phosphate), formulations, and their typical expiry dates?

What the SMPC usually includes:
- A section often titled “Patents” or “Patent status” that lists patent numbers (e.g., WO/EP/US numbers), the scope (composition, salt form, methods of use), and expiry dates or term extensions.
- The information is EU-specific in an SMPC, and may differ from patent listings in the US labeling.

How I can help right away:
- If you can share the SMPC page or a link to the product information for the specific jurisdiction, I can extract and summarize the patent numbers and expiry dates for you.
- If you’d like, I can guide you step-by-step on how to find this in the EU SMPC (EMA website) or the US labeling (FDA) and interpret what it means for patent protection in different regions.

Notes:
- Patent status in the SMPC reflects what is known in that document at the time of publication; it does not guarantee freedom-to-operate.
- The landscape can be dynamic (patent grants/terminations and term extensions).

If you provide the exact product and jurisdiction (for example: EU SmPC for Jakavi, or US label for Jakafi), I’ll pull together a concise summary of the patent information.